Efectos del carvedilol en ratas con insuficiencia renal crónica inducida

Rodríguez Pérez, JC; Cabrera, JJ; Anabitarte, A; Plaza, ML; Losada, A; García Suárez, P; Afonso, JL.
Nefrología (Madr.) ; 21(1): 52-58, ene. 2001.
Artículo en Es | IBECS (España) | ID: ibc-5182

Documentos relacionados

  1. Developmental and reproductive toxicity hazard characterization of 2-amino-2-methyl-1-propanol (AMP).
  2. Cardioprotection with esmolol-based cardioplegia for non-infarcted and infarcted rat hearts.
  3. Letter to the Editor Regarding Article, "Esmolol reduces apoptosis and inflammation in early sepsis rats with abdominal infection".
  4. Upgrading of dissolution and anti-hypertensive effect of Carvedilol via two combined approaches: self-emulsification and liquisolid techniques.
  5. Indicators of haemodynamic instability and left ventricular function in a porcine model of esmolol induced negative inotropy.
  6. Metabolic effects of carvedilol through ß-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts.
  7. [Effects of carvedilol in rats with induced chronic kidney failure].
  8. 16α-OHE1 alleviates hypoxia-induced inflammation and myocardial damage via the activation of ß2-Adrenergic receptor.
  9. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats.
  10. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge.